Aquestive Therapeutics (AQST) Revenue (2017 - 2025)
Historic Revenue for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $12.8 million.
- Aquestive Therapeutics' Revenue fell 542.76% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.2 million, marking a year-over-year decrease of 12233.62%. This contributed to the annual value of $1.0 million for FY2024, which is 9800.72% down from last year.
- Per Aquestive Therapeutics' latest filing, its Revenue stood at $12.8 million for Q3 2025, which was down 542.76% from $10.0 million recorded in Q2 2025.
- Aquestive Therapeutics' 5-year Revenue high stood at $20.1 million for Q2 2024, and its period low was -$44.7 million during Q4 2024.
- In the last 5 years, Aquestive Therapeutics' Revenue had a median value of $11.5 million in 2022 and averaged $8.4 million.
- Per our database at Business Quant, Aquestive Therapeutics' Revenue surged by 30000.0% in 2021 and then tumbled by 43837.65% in 2024.
- Quarter analysis of 5 years shows Aquestive Therapeutics' Revenue stood at $11.1 million in 2021, then decreased by 3.57% to $10.7 million in 2022, then grew by 23.63% to $13.2 million in 2023, then crashed by 438.38% to -$44.7 million in 2024, then surged by 128.66% to $12.8 million in 2025.
- Its Revenue was $12.8 million in Q3 2025, compared to $10.0 million in Q2 2025 and $8.7 million in Q1 2025.